Karen Bieback
Overview
Explore the profile of Karen Bieback including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
5505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azhakesan A, Kern J, Mishra A, Selhuber-Unkel C, Affolter A, Gatenholm P, et al.
Adv Healthc Mater
. 2025 Jan;
e2403114.
PMID: 39801216
Head and neck squamous cell carcinoma (HNSCC) are invasive solid tumors accounting for high mortality. To improve the clinical outcome, a better understanding of the tumor and its microenvironment (TME)...
2.
Keles M, Grein S, Froese N, Wirth D, Trogisch F, Wardman R, et al.
Mol Ther Nucleic Acids
. 2024 Sep;
35(3):102306.
PMID: 39281699
Pathological cardiac remodeling predisposes individuals to developing heart failure. Here, we investigated two co-regulated long non-coding RNAs (lncRNAs), termed and , which are upregulated in failing hearts of patients and...
3.
Fan X, Yang G, Yang Z, Uhlig S, Sattler K, Bieback K, et al.
Biomed Pharmacother
. 2024 Jun;
177:116928.
PMID: 38889637
Endothelial dysfunction contributes to the pathogenesis of Takotsubo syndrome (TTS). However, the exact mechanism underlying endothelial dysfunction in the setting of TTS has not been completely clarified. This study aims...
4.
Trivedi A, Lin M, Miyazawa B, Nair A, Vivona L, Fang X, et al.
Cytotherapy
. 2024 Jun;
26(9):1062-1075.
PMID: 38852094
Background Aims: Mesenchymal stromal cells (MSCs) are attractive as a therapeutic modality in multiple disease conditions characterized by inflammation and vascular compromise. Logistically they are advantageous because they can be...
5.
Rendra E, Crigna A, Daniele C, Sticht C, Cueppers M, Kluth M, et al.
Front Immunol
. 2024 Jan;
14:1228928.
PMID: 38274791
Acute kidney injury (AKI) is characterized by a rapid reduction in renal function and glomerular filtration rate (GFR). The broadly used anti-cancer chemotherapeutic agent cisplatin often induces AKI as an...
6.
Rendra E, Uhlig S, Moskal I, Thielemann C, Kluter H, Bieback K
Cells
. 2024 Jan;
13(2).
PMID: 38247813
(1) Background: The chemotherapeutic drug cisplatin exerts toxic side effects causing acute kidney injury. Mesenchymal stromal cells can ameliorate cisplatin-induced kidney injury. We hypothesize that the MSC secretome orchestrates the...
7.
Tengler L, Tiedtke M, Schutz J, Bieback K, Uhlig S, Theodoraki M, et al.
Sci Rep
. 2024 Jan;
14(1):946.
PMID: 38200037
Small extracellular vesicles from saliva (SEVs) have high potential as biomarkers in Head and Neck cancer (HNC). However, there is no common consensus on the ideal method for their isolation....
8.
Keese M, Zheng J, Yan K, Bieback K, Yard B, Pallavi P, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139026
Adipose-derived stem cells (ASCs) have been used as a therapeutic intervention for peripheral artery disease (PAD) in clinical trials. To further explore the therapeutic mechanism of these mesenchymal multipotent stromal/stem...
9.
Etemad M, Christodoulou F, Uhlig S, Hassel J, Schrotz-King P, Brenner H, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067218
The C-type lectin-like receptor 2 (CLEC-2) is expressed on platelets and mediates binding to podoplanin (PDPN) on various cell types. The binding to circulating tumor cells (CTCs) leads to platelet...
10.
Heuer A, Lowhagen S, Uhlig S, Hetjens S, Buttner S, Pflasterer B, et al.
Transfus Med Hemother
. 2023 Oct;
50(5):417-427.
PMID: 37899990
Introduction: Autologous stem cell transplantation is a successful routine procedure with only a small number of non-engraftment cases, although the time to hematopoietic recovery may vary considerably across patients. While...